

# A comparison of hybrid chemotherapy versus hybrid chemotherapy and autotransplant in poor prognosis Hodgkin's disease

<b>Submission date</b> 19/08/2002	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 19/08/2002	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 13/06/2014	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr - -

**Contact details**  
UKCCCR Register Co-ordinator  
MRC Clinical Trials Unit  
222 Euston Road  
London  
United Kingdom  
NW1 2DA

## Additional identifiers

**Protocol serial number**  
SNLG HDIII

## Study information

**Scientific Title**

**Study objectives**

Not provided at time of registration

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Lymphoma (Hodgkin's)

**Interventions**

All patients receive three 28-day cycles of PVACE-BOP (chlorambucil, procarbazine, etoposide, vinblastine, adriamycin, bleomycin and prednisolone), together with co-trimoxazole every 3 weeks for the duration of treatment.

Patients who achieve at least a partial remission are randomised to one of two treatment regimens:

1. Regimen A: Radiotherapy, 30 Gy in 3 weeks to initially bulky sites or residual areas of disease, followed by two further cycles of PVACE-BOP
2. Regimen B: Radiotherapy, 30 Gy in 3 weeks to initially bulky sites or residual areas of disease, followed by intensive chemotherapy with melphan and etoposide plus autologous bone marrow transplantation.

**Intervention Type**

Other

**Phase**

Not Applicable

**Primary outcome(s)**

Not provided at time of registration

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

31/12/2004

**Eligibility**

## **Key inclusion criteria**

1. Histological diagnosis of Hodgkin's disease
2. Prognostic index of at least 0.5
3. Aged under 60
4. No prior chemotherapy or radiotherapy
5. No known significant heart, lung or renal disease
6. No co-existing malignancies apart from localised skin lesions

## **Participant type(s)**

Patient

## **Healthy volunteers allowed**

No

## **Age group**

Adult

## **Sex**

All

## **Key exclusion criteria**

Not provided at time of registration

## **Date of first enrolment**

01/01/2001

## **Date of final enrolment**

31/12/2004

## **Locations**

### **Countries of recruitment**

United Kingdom

England

### **Study participating centre**

UKCCCR Register Co-ordinator

London

United Kingdom

NW1 2DA

## **Sponsor information**

### **Organisation**

UK Co-ordinating Committee for Cancer Research (UKCCCR)

**ROR**

<https://ror.org/054225q67>

## Funder(s)

**Funder type**

Not defined

**Funder Name**

Not provided at time of registration

## Results and Publications

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/04/2002		Yes	No